High-Risk Neuroblastoma: Current and Future Therapeutic

摘要: High-risk neuroblastoma remains a significant treatment challenge. Currently, less than half of patients survive, despite intensive multi-agent, multimodal therapies. We give an overview the current strategy and summarize evidence for this approach, before discussing options refractory relapsed disease. Finally, we discuss international collaborative efforts to improve by specifically targeting key genetic drivers positively impact on survival.